Maintenance Treatment

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

What is the evidence for time limiting addiction treatment?
Significance of “Unofficial” Ibogaine Treatment Scenes The existence of these scenes indicates demand for alternatives to existing treatment options. Averse.
Maintenance Phase Judith Martin, MD Medical Director, The 14 th Street Clinic, Oakland.
Swinomish Wellness Program
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Sublingual Buprenorphine and Pain
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Developments in Community - Based Drug Treatments Lesley Peters
Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse.
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
Recovery Centers of King County Buprenorphine Treatment Program AAP Providers Conference, April 19, 2013, Lynnwood, WA Patricia C. Knox, Ph.D.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
1 Mental Health and Substance Abuse Services Division Association of Substance Abuse Providers Mike Maples October 5, 2011.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.
The NIDA Clinical Trials is conducting the Prescription Opioid Addiction Treatment Study (POATS) – a multi- site trial examining different lengths and.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Medical issues about Methadone : What the counselor needs to know
Raymond F. Anton, MD for The COMBINE Study Research Group
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
 Is buprenorphine that good?  Is medical management (MM) that good?  Is counseling that ineffective for this population?  Have the studies been designed.
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Accessibility, Pattern of Use and Implications of Restricted Availability of Medicines for Treatment of Substance Abuse in a Tertiary Level Health Care.
CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.
Medication Assisted Treatment for Opioid Use Disorders
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
SHARED MEDICAL APPOINTMENTS Achieving Better Patient Outcomes and Organizational Efficiencies Part 2 Provided as an educational service by Pfizer Inc.
An Alternative to Data Imputation in Analgesic Clinical Trials David Petullo, Thomas Permutt, Feng Li Division of Biometrics II, Office of Biostatistics.
Arthur Robin Williams, M.D. October 13, 2016 Medication-Assisted Treatment (MAT): Maintenance, Treatment, and Outcomes If you have any questions/comments.
MAT Medication Assisted Treatment
Differences in Treatment Outcome and Current Cognitive and Behavioral Functioning of Individuals Who Received Ibogaine-Assisted Treatment for a SUD Alan.
Opioid Medication Assisted Tx (1)
Alcohol, Other Drugs, and Health: Current Evidence
Alcohol, Other Drugs, and Health: Current Evidence
Steps of Medication Abortion
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Medication-Assisted Treatment 101: Breaking the Stigma
Warfarin Prescribing.
Evaluation of California’s Hub and Spoke System
RIDOC BASED MAT FOR OPIATE USE DISORDERS
DiRECT (Diabetes Remission Clinical Trial)
PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Fig. 1. MAHALO clinical trial flowchart.
The Research Question Background: Question:
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The relationship between incarceration and opioid addiction treatment
Medications used in Treatment of Alcohol and Drug Use Disorders
Alcohol, Other Drugs, and Health: Current Evidence
Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.
Bassett-UMass MAT ECHO.
Presentation transcript:

Maintenance Treatment Relapse rates for stably maintained patients is as high as 82% within 1 year off of methadone Ball et al. The Effectiveness of Methadone Treatment. New York: Springer-Verlag; 1991

Taper or Maintenance Treatment Outcome Maintenance Taper Abstinence 53% 35% Days per week of opioid use 0.47 days 1.27 days Consecutive weeks of abstinence 5.2 weeks 2.7 weeks Trial completion 66% 11% 14 week study at a primary care site. 113 patients randomized to taper or maint on bup over 14 weeks. Taper started at week 6- patients received treatment for withdrawal, more counseling, and were offered naltrexone (only two picked this route). Outcomes: opioid use, treatment retention, reinitiation of bup. Fiellin DA et al. JAMA Intern Med 2014;174:1947-1954

Opioid Use after Discontinuation Approx Relapse Rates 50-80% 90% 80% 65% 55% Study Sample Size Maint Period Mean Dose Abstinent Maint Taper Duration Follow-up Time NTX Abstinent post-taper Sigmon et al. 2013 70 2 wks 11.5mg 82% 1 wk 2 wk 4 wk 9 wks 8 wks 6 wks 50mg 21% 17% 50% Weiss et al. 2011 323 12 wks 20.8mg 54% 4 wks None 9.6% Ling et al. 2009 516 20.3mg 37% 18% Woody et al. 2008 55 15.1mg 6 months 34% Breen et al. 2003 50 2 wks (>6 months MMT) 8.6mg NR 11 wks Optional (N=5) 44% Bentzley et al. J Subst Abuse Treat 2015;52:48-57

Induction Strategies

Induction Strategies Office Home Patient centered approach becoming more widely implemented No need to time withdrawal around clinic schedule Fewer demands on space and clinic staff Standard used since introduction in U.S. Close monitoring for response and dose adjustments Appropriate for patients with limited social supports and unstable housing

Home Induction Protocol Lee JD et al. J Gen Intern Med 2009;24:226-232

Evidence for Home Induction J Subst Abuse Treat 2011 Jun; 40(4): 349–356